Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial-Reference-Cited by-同舟云学术

Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial

Published:2020-12 Issue: Volume:170 Page:108487
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Guo Wen,Tian Wenjun,Lin Lu,Xu Xiangjin

Funder

Natural Science Foundation of Fujian Province

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference37 articles.

1. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health[J];Rinella;Hepatology,2016

2. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a system-atic review and meta-analysis;Younossi;J Hepatol,2019

3. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults;Vernon;Aliment Pharmacol Ther,2011

4. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups;Lonardo;Dig Liver Dis,2015

5. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease;Manchanayake;J Gastroenterol Hepatol,2011

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review;Frontiers in Pharmacology;2024-09-03

2. Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD;Diabetes Research and Clinical Practice;2024-08

3. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies;World Journal of Methodology;2024-06-20

4. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis;Metabolic Syndrome and Related Disorders;2024-06-13

5. Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials;Journal of Diabetes and its Complications;2024-06